Episode 32
48mins
In this second part of our deep dive into hematology and oncology, we welcome back Dr. Yaming Wang, founder of Alphabet Health LTD and an expert in molecular oncology, pharmaceutical strategy, and medical education. Building on our previous discussion, we explore cutting-edge advancements in cancer diagnostics and therapies, including the promise and limitations of liquid biopsies, the evolution of immunotherapy, and the expanding role of CAR-T and antibody-drug conjugates.
But innovation alone isn’t enough—how do we ensure these breakthroughs reach the patients who need them most? We tackle the challenges of healthcare communication, provider education, and patient access, examining how AI, public health initiatives, and systemic change can bridge the gap between scientific progress and real-world impact.
Join hosts Dr. Na-Ri Oh and Ian Wendt for an engaging and thought-provoking conversation that not only highlights the science behind cancer treatment but also the urgent need to make these life-saving therapies more widely accessible. Don't miss this critical discussion on the future of oncology!
Comments